An Amphipathic α-Helix Directs Palmitoylation of the Large Intracellular Loop of the Sodium/Calcium Exchanger by Plain, Fiona et al.
                                                              
University of Dundee
An Amphipathic -Helix Directs Palmitoylation of the Large Intracellular Loop of the
Sodium/Calcium Exchanger
Plain, Fiona; Congreve, Samitha Dilini; Zhen Yee, Rachel Sue; Kennedy, Jennifer; Howie,
Jacqueline; Kuo, Chien-Wen; Fraser, Niall J.; Fuller, William
Published in:
Journal of Biological Chemistry
DOI:
10.1074/jbc.M116.773945
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Plain, F., Congreve, S. D., Zhen Yee, R. S., Kennedy, J., Howie, J., Kuo, C-W., ... Fuller, W. (2017). An
Amphipathic -Helix Directs Palmitoylation of the Large Intracellular Loop of the Sodium/Calcium Exchanger.
Journal of Biological Chemistry, 292(25), 10745-10752. DOI: 10.1074/jbc.M116.773945
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
An amphipathic -helix directs palmitoylation of the large
intracellular loop of the sodium/calcium exchanger
Received for publication,December 22, 2016, and in revised form, April 19, 2017 Published, Papers in Press, April 21, 2017, DOI 10.1074/jbc.M116.773945
Fiona Plain, Samitha Dilini Congreve, Rachel Sue Zhen Yee, Jennifer Kennedy, Jacqueline Howie, Chien-Wen Kuo,
X Niall J. Fraser, and X William Fuller1
From the Division of Molecular and Clinical Medicine, School of Medicine, Ninewells Hospital, University of Dundee,
Dundee DD1 9SY, Scotland, United Kingdom
Edited by Henrik G. Dohlman
The electrogenic sodium/calcium exchanger (NCX)mediates
bidirectional calcium transport controlled by the transmem-
brane sodium gradient. NCX inactivation occurs in the absence
of phosphatidylinositol 4,5-bisphosphate and is facilitated by
palmitoylation of a single cysteine at position 739 within the
large intracellular loop of NCX. The aim of this investigation
was to identify the structural determinants of NCX1 palmitoy-
lation. Full-length NCX1 (FL-NCX1) and a YFP fusion pro-
tein of the NCX1 large intracellular loop (YFP-NCX1) were
expressed in HEK cells. Single amino acid changes around Cys-
739 in FL-NCX1 and deletions on the N-terminal side of Cys-
739 in YFP-NCX1 did not affect NCX1 palmitoylation, with
the exception of the rare human polymorphism S738F, which
enhanced FL-NCX1 palmitoylation, and D741A, which mod-
estly reduced it. In contrast, deletionof a 21-aminoacid segment
enriched in aromatic amino acids on the C-terminal side of Cys-
739 abolishedYFP-NCX1palmitoylation.Wehypothesized that
this segment forms an amphipathic -helix whose properties
facilitate Cys-739 palmitoylation. Introduction of negatively
charged amino acids to the hydrophobic face or of helix-break-
ing prolines impaired palmitoylation of both YFP-NCX1 and FL-
NCX1. Alanine mutations on the hydrophilic face of the helix sig-
nificantly reduced FL-NCX1 palmitoylation. Of note, when the
helix-containing segment was introduced adjacent to cysteines
that are not normally palmitoylated, they became palmitoylation
sites. In conclusion, we have identified an amphipathic -helix in
the NCX1 large intracellular loop that controls NCX1 palmitoyla-
tion.NCX1palmitoylation is governed by a distal secondary struc-
ture element rather than by local primary sequence.
Transmembrane calcium movement by electrogenic sodi-
um/calcium exchangers (NCX)2 is a vital signaling event in
multiple tissues. By controlling calcium dynamics in both
smooth and striated muscle, for example, NCX is an important
regulator of the contractility of skeletal, cardiac, and vascular
smooth muscle. NCX can mediate either calcium extrusion
(forwardmode) or calcium influx (reversemode) depending on
the prevailing sodium and calcium gradients and the mem-
brane potential. Three NCX isoforms exist in mammalian
genomes. NCX1 is widely expressed and has multiple splice
variants (NCX1.1 is the principal variant in cardiac muscle (1)).
NCX2 andNCX3 are expressed in brain and skeletalmuscle (2).
The NCX1 transmembrane architecture consists of two
inverted repeats, each composed of five membrane-spanning
helices (3, 4). The transmembrane domains are sufficient for
exchanger activity (5), and regulation is mediated by a large
(550 residues) intracellular loop between transmembrane
domains 5 and 6. Calcium binding to two calcium-binding
domains (CBDs) (CBD1, residues 370–501 in the mature
exchanger, and CBD2, residues 501–599) facilitates calcium
activation of NCX1 (6, 7). Sodium inactivates NCX1 (8), and
this requires a region at the N-terminal end of the intracellular
loop named the exchanger inhibitory peptide (XIP domain, res-
idues 219–238 in the mature exchanger (9)). XIP itself inhibits
NCX1 and is proposed to interact directly with a region encom-
passed by residues 562–679 (including part of CBD2, at the
C-terminal end of the large intracellular loop) to achieve this
(10).
Palmitoylation is the reversible attachment of a fatty acid
(most commonly palmitate) to a cysteine sulfhydryl via a thio-
ester bond. By recruiting the palmitoylated cysteine to the inner
face of the phospholipid membrane, palmitoylation has the
potential to impose significant structural and therefore func-
tional changes on proteins (11). Many different types of pro-
teins are palmitoylated; palmitoylation can regulate membrane
association, cellular distribution, trafficking, and turnover, as
well as enzymatic activity, phospholipid interactions, and chan-
nel/transporter activity (11–13). NCX1 is palmitoylated at a
single cysteine at position 739 of its large intracellular loop (14).
Exchangers that cannot be palmitoylated do not inactivate nor-
mally, leading to substantial activity in conditions when wild-
type exchangers are inactive (14, 15). The NCX1 palmitoylated
cysteine is conserved among all NCX isoforms in vertebrates.
Limited structural information is available for theNCX1 reg-
ulatory intracellular loop. X-ray and NMR structures of CBD1
and CBD2 both in isolation and together provide insight into
calcium regulation of NCX1 (7, 16–18), but the region contain-
This work was supported by British Heart Foundation Grants RG/12/4/29426
and PG/16/33/32134 (to W. F.) and Grant FS/14/68/30988 (to W. F. and
N. J. F.). The authors declare that they have no conflicts of interest with the
contents of this article.
This article was selected as one of our Editors’ Picks.
Author’s Choice—Final version free via Creative Commons CC-BY license.
1 To whom correspondence should be addressed: Division of Molecular and
Clinical Medicine, Mail Box 12, Level 5, Ninewells Hospital, Dundee DD1
9SY, Scotland, United Kingdom. Tel.: 01382-383089; Fax: 01382-383598;
E-mail: w.fuller@dundee.ac.uk.
2 The abbreviations used are: NCX, sodium/calcium exchanger; FL-NCX1, full-
length NCX1; CBD, calcium-binding domain; PAT, palmitoyl acyltrans-
ferase; SNP, single nucleotide polymorphism.
cros
EDITORS’ PICK
Author’s Choice
J. Biol. Chem. (2017) 292(25) 10745–10752 10745
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on July 13, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ing the palmitoylation site is essentially uncharacterized struc-
turally. The section of the loop immediately C-terminal to the
palmitoylation site was originally proposed to form transmem-
brane helix 6 of NCX1, but its localization was revised to cyto-
solic based on cysteine accessibility assays (19). A crystal struc-
ture of a bacterial homologue of NCX subsequently confirmed
this and identified amino acid 761 as the start of transmem-
brane domain 6 of human NCX1 (4).
Like full-length NCX1, a YFP fusion protein of the NCX1
large intracellular loop is palmitoylated at Cys-739, indicating
palmitoylation occurs independent of the presence of the
NCX1 transmembrane domains (14) and that the palmitoyla-
tion “signal” for Cys-739 resides within this loop. Although
there are multiple cysteines in the NCX1 intracellular loop,
only Cys-739 is palmitoylated. The aim of this investigationwas
to identify the sequence determinants in the NCX1 intracellu-
lar loop that direct palmitoylation of Cys-739. We report that
the section of this loop previously annotated as transmembrane
domain 6 is required for NCX1 palmitoylation, and we suggest
that the hydrophilic face of this largely hydrophobic -helix is
recognized by the cellular palmitoylation machinery.
Results
Amino acid substitutions close to the NCX1 palmitoylation site
are largely without effect on NCX1 palmitoylation
Post-translational modifications such as phosphorylation
is usually dictated by protein kinases recognizing primary
sequence features local to the phosphorylation site. Palmitoy-
lation prediction algorithms based on the primary sequence
will only be valuable if the same recognition principle applies to
acyltransferases.We therefore investigated whether changes to
the primary sequence around the NCX1 palmitoylation site
impaired the ability of the NCX1 acyltransferase to recognize
and palmitoylate Cys-739. We first evaluated the effect of
changing the amino acids surrounding Cys-739 to alanine on
palmitoylation of full-length NCX1. Mutants K735A, L736A,
P737A, S738A, F740A, D741A, Y742A, and V743A of NCX1
were assessed alongside wild-type and C739A (unpalmitoylat-
able) NCX1. With the exception of D741A, which displayed
moderately reduced palmitoylation compared with wild type,
none of the mutations affected NCX1 palmitoylation (Fig. 1A).
We also evaluated the impact of neutralizing (E733A/E734A)
negative charges located N-terminal to Cys-739 or replacing
them with positive ones (E733K/E734K) on NCX1 palmitoyla-
tion (Fig. 1B). In addition, we inserted an alanine either imme-
diately before (InsA739) or immediately after (InsA740) the
palmitoylated cysteine, changing the relative position of either
all “upstream” or all “downstream” residues (Fig. 1B). Once
again, all substitutions and insertions had no effect on the
palmitoylation of Cys-739, strongly implying that in contrast to
protein kinases the primary sequence surrounding Cys-739 has
negligible impact on its palmitoylation.
Singlemutation adjacent to the NCX1 palmitoylation site
increases NCX1 palmitoylation
We next investigated the impact of two validated but rare
single nucleotide polymorphisms (SNPs) of human NCX1 on
its palmitoylation. SNPs rs371485750 and rs373510583 gener-
ate the missense mutations P737L and S738F, respectively,
albeit with very low minor allele frequencies. Substitution of
Ser-738 with a bulky phenylalanine residue increased the frac-
tion of full-length NCX1 palmitoylated at Cys-739 in HEK cells
comparedwith wild type, whereas replacement of Pro-737with
leucine was without effect (Fig. 2A). Neither mutation pre-
vented the expression ofNCX1 at the cell surface assessed using
membrane-impermeable biotinylation reagents (Fig. 2B).
Amphipathic-helix distal and C-terminal to Cys-739 is
required for NCX1 palmitoylation
Having established that the local primary sequence has a neg-
ligible effect on NCX1 palmitoylation, we sought to identify
those regions within the NCX1 intracellular loop required for
its palmitoylation by truncating the loop fromboth theN andC
Figure 1. Palmitoylation of NCX1 is largely independent of primary
sequence close to the palmitoylation site. Palmitoylated proteins were
purified by resin-assisted capture and immunoblotted alongside their
respective unfractionated cells lysates. In all experiments palmitoylation is
expressed relative to expression. A, single amino acid substitutions with ala-
nine do not influence NCX1 palmitoylation with the exception of D741A,
which modestly reduces palmitoylation. B, charge substitutions and inser-
tions before or after Cys-739 are without impact on NCX1 palmitoylation. UF,
unfractionated cell lysate; Palm,palmitoylatedproteins. *, p 0.05 versusWT;
**, p 0.01 versusWT, n 5–6.
Amphipathic-helix directs NCX1 palmitoylation
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termini (Fig. 3A). A YFP fusion protein with the NCX1 intra-
cellular loop (amino acids 266–765, from the end of the XIP
domain to TM6) is palmitoylated in HEK cells (Fig. 3B). N-ter-
minal truncations successively removed the region between
XIP and CBD1 (residues 266–370), CBD1 (residues 370–501),
CBD2 (residues 501–599), and the proposed catenin-like
domain (17) adjacent to CBD2 (residues 599–690). All were
without effect on the palmitoylation of YFP-NCX1 (Fig. 3B). In
contrast, removal of 21 amino acids on the C-terminal side of
the NCX1 palmitoylation site (residues 744–765) completely
abolished NCX1 palmitoylation in HEK cells (Fig. 3B).
Residues 745–765 of NCX1 include a region initially anno-
tated as a transmembrane helix, whose cytosolic location was
later established by cysteine accessibility assays (19). The sec-
ondary structure prediction algorithm Jpred4 (20) suggests
with high confidence that residues 740–757 of NCX1 form an
-helix (Fig. 3C). A helical wheel projection (Fig. 3C) indicates
that this helix is expected to have a small hydrophilic face (res-
idues D741, H745, T748, and K752 highlighted in black), with
the remainder of the helix hydrophobic in character and rich in
aromatic amino acids, particularly on one face (F746, F750, and
F757). We hypothesized that the amphipathic nature of this
helix but (given the lack of impact of mutant InsA740 on Cys-
739 palmitoylation) not its location was critical for palmitoyla-
tion of NCX1. To explore this possibility, a series of mutagen-
esis experiments were performed. Mutation of aromatic amino
acids within the proposed helix to alanine either individually or
in combination did not alter palmitoylation of YFP-NCX1 (not
shown: Y742A, F746A, F750A, W751A, and F755A). Next, we
assessed the impact of introducing helix-breaking prolines and
membrane-repelling glutamates to this helix on the palmitoy-
lation of YFP-NCX1 (residues 266–765). Introduction of a sin-
gle negative charge at positionPhe-746 (F746E) reduced but did
not abolish palmitoylation of YFP-NCX1, whereas either intro-
ducing a single negative charge at position Phe-750 (F750E) or
introducing three helix-breaking prolines (M744P/H745P/
F746P) both abolished YFP-NCX1 palmitoylation (Fig. 4).
Deletion of either the whole proposed helix (740–756), the
first two turns (740–746), or the second two turns (747–
753) also abolished palmitoylation of YFP-NCX1 (Fig. 4), sug-
gesting the whole -helix is the minimum region required to
direct YFP-NCX1 palmitoylation.
Amphipathic-helix on the C-terminal side of the NCX1
palmitoylation site is required for palmitoylation but not
trafficking of full-length NCX1
We next investigated the impact of the mutations character-
ized in Fig. 4 on palmitoylation and trafficking of full-length
NCX1 (FL-NCX1). Although palmitoylation is not required for
passage of NCX1 through the secretory pathway (14), muta-
tions disrupting the endoplasmic reticulum exit through mis-
folding of FL-NCX1 would reduce palmitoylation, as NCX1 is
palmitoylated in the Golgi (14). Mutation F746E/F750E abol-
ished palmitoylation ofNCX1 (Fig. 5A), but it also prevented its
delivery to the cell surface (Fig. 5B), suggesting that this mutant
was misfolded. F746E and F746A/F750A were palmitoylated
and trafficked normally, whereasmutant F750E reduced palmi-
toylation but not trafficking of FL-NCX1.No alaninemutations
of aromatic amino acids within the proposed helix impacted
palmitoylation of FL-NCX1 (not shown: F746A, F750A,
W751A, and F755A). Deletion of the predicted amphipathic
-helix (740–756) or breaking this -helix (M744P/H745P/
F746P) largely abolished palmitoylation but not cell surface
delivery of FL-NCX1. Palmitoylation of FL-NCX1 was sus-
tained in the absence of the second two turns of the proposed
helix (746–753, in contrast to YFP-NCX1) but abolished in
the absence of the first two (740–746).
Amphipathic-helix is capable of directing palmitoylation of
cysteines that are not normally palmitoylated
We investigated the ability of the amphipathic -helix
required for palmitoylation of Cys-739 to “confer” palmitoyla-
tion on another cysteinewithinNCX1 that is not usually palmi-
toylated. By removing amino acids 732–739 from NCX1
(including the normal palmitoylation site) the putative helical
Figure 2. Palmitoylation and trafficking of human polymorphisms of
NCX1.A, substitutionof Ser-738with abulky phenylalanine residue increases
the fraction of NCX1 palmitoylated in HEK cells, but P737L is without effect. B,
polymorphisms P737L and S738F arewithout impact on the delivery of NCX1
to the cell surface. EV, empty vector transfected cells; UF, unfractionated cell
lysate; palm, palmitoylated proteins **, p 0.01 versusWT, n 7.
Amphipathic-helix directs NCX1 palmitoylation
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recognition element was positioned immediately adjacent to
Cys-731 (which is not usually palmitoylated). Fig. 5C indicates
that the 732–739 NCX1 mutant was palmitoylated at Cys-
731, despite the presence of seven consecutive negatively
charged residues (724EDDDDDE730) on the immediate N-ter-
minal side of Cys-731.
In an additional “gain-of-function” experiment, we added
NCX1 residues 738–756 (including both palmitoylated cys-
teine and amphipathic -helix) to the C terminus of YFP. As a
result, YFP was palmitoylated (Fig. 5D) and tethered to intra-
cellular membranes in a manner indistinguishable from YFP-
NCX1 (Fig. 5E).
Hydrophilic face of the amphipathic-helix is required for
palmitoylation of NCX1 Cys-731
We investigated the impact of changing the four residues on
the hydrophilic face of the amphipathic-helix to alanine. Sub-
stitution of Asp-741, His-745, Thr-748 but not Lys-752 with
alanine reduced palmitoylation of FL-NCX1, with the largest
reduction observed when His-745 was mutated. The most sig-
nificant impact on FL-NCX1 palmitoylation was achieved by
the substitution of all four residues on the hydrophilic face with
alanine (D741A/H745A/T748A/K752A, Fig. 6); NCX1 palmi-
toylation was reduced by85%, similar to the effect of remov-
ing the amphipathic -helix altogether.
Discussion
Here we identify the region of the NCX1 intracellular loop
that directs its palmitoylation, as well as determining the prop-
erties of this region required for both palmitoylation and traf-
ficking of NCX1. Palmitoylation of NCX1 is determined by sec-
ondary rather than primary structure; residues 740–756 are
required forNCX1 to be palmitoylated. Disruption of either the
-helical geometry, the introduction of more than one nega-
tively charged amino acid to the hydrophobic face, or alanine
mutagenesis of the hydrophilic face of this helix all drastically
Figure 3. Palmitoylation of YFP-NCX1 requires an amphipathic -helix on the C-terminal side of the palmitoylation site. A, schematic of the NCX1
intracellular loop, indicating the positions of the calcium-binding domains (CBD), catenin-like domain (CLD), and amphipathic -helix (AH). The positions of
truncations are indicated below the schematic. B, impact of truncations on the palmitoylation of YFP-NCX1. Only removal of amino acids 744–765 causes
palmitoylation of Cys-739 tobe abrogated.C, sequence ofNCX1 residues 739–765, highlighting the abundant aromatic amino acids (). Theunderlined region,
744–765, is required for palmitoylation of NCX1 in B. The boxed region is predicted to form an -helix by JPred4. A projection of this -helix is shown, with the
polar face highlighted in black. UF, unfractionated cell lysate; Palm, palmitoylated proteins. **, p 0.01 versus 266–765 (WT), n 5.
Amphipathic-helix directs NCX1 palmitoylation
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reduce or abolish NCX1 palmitoylation. Interestingly this
region is 100% identical in both NCX2 and NCX3, but with
cysteines at both N- and C-terminal ends of the helix (analo-
gous to positions 739 and 757 inNCX1). These cysteines would
appear on the same face of the -helix, which we suggest may
support dual palmitoylation of these NCX family members.
Surprisingly,NCX1 residues 740–756 are dispensable for the
trafficking of full-length NCX1 to the cell surface, but when
present this region must be largely hydrophobic (no more than
one additional negatively charged amino acid can be accommo-
dated) but not necessarily -helical (helix-breaking prolines do
not abolish trafficking).
On first sight, our data may appear to be consistent with a
model in which weak membrane interaction of a cytosolic
region of a protein orients a cysteine appropriately for transfer
of palmitate from a palmitoylating acyltransferase enzyme. The
lack of impact of mutant InsA740 on NCX1 palmitoylation
suggests the position of Cys-739 relative to this helix is unim-
portant. Indeed, the palmitoylation of substrates by Golgi-lo-
calizedAsp-His-His-Cys-containing palmitoyl acyltransferases
(DHHC-PATs) has been argued to be largely stochastic, with-
out specific enzyme/substrate pairs (21). However, the deletion
of residues 740–756 of full-lengthNCX1will also position Cys-
739 very close to the membrane (transmembrane domain 6
starts at position 761 (4)) but notably does not support its
palmitoylation. Even in the presence of this amphipathic helix,
unpalmitoylatable C739A YFP-NCX1 is not found membrane-
associated (14). There is evidently greater specificity to the
palmitoylation reaction for NCX1 than a simple random event.
Certain DHHC-PATs recognize substrates via the formation of
stable protein-protein interactions in regions of the enzyme
separated from the catalytic site (22–25). Indeed, in some cases
regions distant from the palmitoylated cysteine have been
found to control palmitoylation (26).We therefore suggest that
the hydrophilic face of NCX1 residues 740–756 is responsible
for interaction with the palmitoylating DHHC-PAT. Consist-
ent with this, positioning this region adjacent toNCX1Cys-731
supports palmitoylation of this site and is sufficient to direct
palmitoylation of YFP. The ability of the amphipathic -helix
identified in this investigation to drive palmitoylation of cys-
teines that are not normally palmitoylated may therefore have
biotechnology applications, for example in reversibly anchor-
ing soluble proteins to the Golgi apparatus. Equivalent motifs
likely exist directing palmitoylation of particular cysteines by
DHHC-PATs in other cellular compartments.
We find minor differences between the palmitoylation of
YFP-NCX1 and full-length NCX1 that imply the presence of
transmembrane domains (and possibly proximity to the mem-
brane) can also influence palmitoylation of a particular cys-
teine. Mutants F746E and F750E are essentially unpalmitoy-
lated in the absence of transmembrane domains, but F746E
does not influence palmitoylation of full-length NCX1, and
F750E only modestly reduces it. Similarly, deletion of the sec-
ond half of the amphipathic -helix (747–753) abolishes
palmitoylation of YFP-NCX1, but it is without effect on full-
length NCX1. The importance of the second half of this helix
for NCX1 palmitoylation is emphasized by the reduced palmi-
toylation in the presence ofmutationT748Aon the hydrophilic
face. Nevertheless, our data indicate that proximity to the
membrane (the presence of transmembrane domains) “loos-
ens” the required consensus for NCX1 palmitoylation as fol-
lows: the first two turns of the helix are essential, but the
absence of the second two turns can bemitigated by transmem-
brane domains positioning Cys-739 close to the membrane.
Several palmitoylation prediction tools developed in recent
years have attempted to define a palmitoylation “consensus
sequence” (27–29). Three recent studies have suggested hydro-
phobic residues on the N-terminal side and basic residues on
the C-terminal side of a particular cysteine will favor its palmi-
toylation (28, 30, 31). Clearly, this is not the case for NCX1; the
N-terminal side of the palmitoylation site is enriched in nega-
tively charged amino acids (9 of the first 20 residues on the
N-terminal side are aspartate or glutamate), and the carboxyl
side is hydrophobic. Indeed, the fact that when positioned adja-
cent to Cys-731, NCX1 residues 740–756 are capable of induc-
ing palmitoylation of this site (despite the abundant negative
charges on the N-terminal side) emphasizing the difficulty of
using palmitoylation predictors based on primary sequence.
Substrate recognition byDHHC-PATs is clearly fundamentally
different from protein kinases; phosphorylation sites can be
accurately predicted based on primary sequence (although cer-
tain kinases and phosphatases also rely on interactions outside
the active site (32)). As palmitoyl proteomes and palmitoylation
sites are catalogued and DHHC-PATs are better characterized,
the sequence rules for identifying palmitoylation sites may
Figure 4. Palmitoylation of YFP-NCX1 is abolished by mutations in the
C-terminal -helix. Introduction of a single negative charge at position 746
(F746E) reduces but does not eliminate palmitoylation of YFP-NCX1, whereas
palmitoylation is completely abolished either by introducing a negative
charge in position 750 (F750E), two negative charges (F746E/F750E), or the
helix-breaking insertion of three prolines (M744P/H745P/F746P). Deletion of
the entire -helix (740–756), the first two turns of the helix (740–746), or
the second two turns of the helix (747–753) also prevents or reduces YFP-
NCX1 palmitoylation. UF, unfractionated cell lysate; Palm, palmitoylated pro-
teins. **, all p 0.01 versusWT, n 4.
Amphipathic-helix directs NCX1 palmitoylation
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Amphipathic-helix directs NCX1 palmitoylation
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improve. Low specificity “stochastic” palmitoylation sites may
well prove amenable to identification simply by inspecting pri-
mary sequences, but palmitoylation events that rely on stable
interactions between DHHC-PAT and substrate will likely not,
and will have to be determined experimentally. Because no
mutations on the N-terminal side of Cys-739 impaired NCX1
palmitoylation, we suggest that the enhanced palmitoylation of
the naturally occurring NCX1 polymorphism S738F may rep-
resent an impairment of NCX1 depalmitoylation. Most likely
the flanking of the palmitoylated cysteine with bulky phenyla-
lanines (Phe is also in position 740) impairs the ability of the
NCX1 thioesterase to access the thioester bond at Cys-739.
Hence, our data also suggest an experimental strategy for gain-
of-function experiments to specifically enhance the palmitoy-
lation of proteins. The use of negatively charged amino acids as
phosphomimetic mutants is widespread in understanding the
role of phosphorylation of individual residues. To date, such an
approach has not been available to investigate the biology of
protein palmitoylation.
In conclusion, we have identified an amphipathic -helix at
theC-terminal end of theNCX1 intracellular loop that controls
palmitoylation of NCX1. Palmitoylation of NCX1, and likely
other proteins, is directed by secondary rather than primary
structure.
Experimental procedures
Antibodies
Anti-NCX1 was from Swant; anti-flotillin 2 was from BD
Biosciences; anti-GAPDH was from Sigma; and anti-GFP was
from Abcam. The monoclonal antibody 6F raised against
the sodium pump 1 subunit by Douglas M. Fambrough was
obtained from the Developmental Studies Hybridoma Bank
developed under the auspices of the NICHD, National Insti-
tutes of Health, and maintained by the Department of Biology,
University of Iowa.
Purification of palmitoylated proteins
Palmitoylated proteins were purified using thiopropyl-Sep-
harose in the presence of neutral hydroxylamine after alkyla-
tion of free thiols with methyl methanethiosulfonate, as
described previously (22).
Purification of cell-surface proteins
Representative fractions of cell-surface proteins were pre-
pared by treating cells with 1 mg/ml sulfo-NHS-SS-biotin
(Pierce) for 10 min at 37 °C to biotinylate integral surface mem-
braneproteinswithextracellularprimaryamines,whichwere sub-
sequently purified using streptavidin-Sepharose (GEHealthcare).
Plasmids, cell lines, and transfection
The plasmids used were based on canine NCX1.1 and are
described elsewhere (14). Amino acid numbering is for the car-
diac splice variant NCX1.1 with the signal peptide removed.
FL-NCX1 typically migrated on SDS-PAGE as bands 120 and
160 kDa in size, although the presence of the 160-kDa species
was not consistent. All transfections of plasmid DNA used
Lipofectamine 2000 (Invitrogen) according to the manufactu-
rer’s instructions.
Site-directedmutagenesis
Mutagenesis reactions were performed with the Quikchange
II site-directed mutagenesis kits (Agilent). Mutagenesis prim-
ers were designed using the Agilent on-line primer design tool.
Microscopy
Images were acquired from cells fixed in 4% paraformalde-
hyde 24 h after transfection using a Leica SP5 confocal micro-
scope. Acquisition parameters were (excitation/emission, nm)
YFP, 519/542.
Quantitative and statistical analysis
Western blottings were acquired using a ChemiDoc XRS
imaging system and images quantitated using theQuantityOne
Figure 5. Point mutations and palmitoylation of full-length NCX1. A, point mutations F746E/F750E, 740–756, 740–746, and M744P/H745P/F746P
prevent palmitoylation of full-length NCX1, whereas F750E reduces full-length NCX1 palmitoylation, and 747–753 and F746E are without effect. B, of the
mutations assessed inA, only F746E/F750E impedes progression of full-lengthNCX1 through the secretory pathway.C,NCX1 is palmitoylated at Cys-731when
the region usually on the C-terminal side of Cys-739 is instead positioned adjacent to Cys-731. D, C-terminal fusion of NCX1 residues 738–756 is sufficient to
direct palmitoylation of YFP. E, C-terminal fusion of NCX1 residues 738–756 anchors YFP to intracellular membranes in a manner indistinguishable from
YFP-NCX1. Scale bar, 20 m. *, p 0.05 versusWT; **, p 0.01 versusWT, n 5.
Figure 6. Alanine mutations on the hydrophilic face of the amphipathic
-helix impair NCX1 palmitoylation. Substitution of Asp-741, His-745, and
Thr-748 but not Lys-752 reduce palmitoylation of full-length NCX1. Substi-
tution of all four residues on the hydrophilic face with alanine (All4A:
D741A/H745A/T748A/K752A) reduces NCX1 palmitoylation by85%, UF,
unfractionated cell lysate; Palm, palmitoylated proteins. **, p 0.01 versus
WT, n  4.
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software package (Bio-Rad). Band intensity in the “palmitoy-
lated” fraction was normalized to the corresponding unfrac-
tionated cell lysate. To account for day-to-day variations in
palmitoylation stoichiometry, individual data points were nor-
malized to the groupmean for that particular experimental day.
Identical results were obtained by normalizing individual data
points to the palmitoylation of wild-type NCX1 on that partic-
ular experimental day. Quantitative data are presented as
means  S.E. The differences between experimental groups
were analyzed by one-way analysis of variance, followed by post
hoc t tests. Differences were considered statistically significant
with p 0.05.
Author contributions—F. P. performed and analyzed experiments
shown in Figs. 1, 2, and 4–6. S. D. C. performed and analyzed exper-
iments shown in Figs. 4 and 5. R. S. Z. Y. performed and analyzed
experiments shown in Figs. 1 and 3. J. H. performed and analyzed
experiments show in Figs. 1–3. J. K. and C.-W. K. performed
and analyzed experiments shown in Fig. 5. W. F. and N. J. F. con-
ceived the idea for theproject andwrote thepaper.All authors reviewed
the results and approved the final version of themanuscript.
Note added in proof—There was some textual overlap between the
version of this article that was published as a Paper in Press on April
21, 2017, and Reilly, L., Howie, J., Wypijewski, K., Ashford, M. L.,
Hilgemann, D. W., and Fuller, W. (2015) FASEB J. 29, 4532–4543.
The overlap has now been removed.
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